Sean Harper

Type: Person
Name: Sean Harper
First reported 6 hours ago - Updated 4 hours ago - 2 reports

Amgen Heart Study Shows Positive Ivabradine Results

Amgen announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart ... [Published Drug Discovery and Development - 4 hours ago]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Amgen applies for EU approval of new melanoma drug

:08 in Pharmaceutical Company Product News Amgen has applied for European Medicines Agency approval of an investigational oncolytic immunotherapy for the treatment of regionally or distantly metastatic melanoma. A marketing authorisation application has ... [Published Zenopa - Sep 08 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 1 reports

Amgen Submits Cholesterol Drug for EMA Approval

Amgen announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational ... [Published Drug Discovery and Development - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Amgen files for EU approval of talimogene laherparepvec and for evolocumab02-09-2014

Leading independent biotech firm Amgen (Nasdaq: AMGN) has submitted a Marketing Authorization Application to the European Medicines Agency via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma ... [Published Pharma Letter - Sep 03 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 7 reports

Amgen submits next gen cholesterol drug

Amgen has put itself in pole position in the race to market the next generation of injectable statins known as PCSK9 inhibitor, after submitting evolocumab to the FDA.This makes the US biotech giant the first to seek approval of a medicine from a closely-watched ... [Published Pharmafocus - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 4 reports

Amgen gets priority review for chronic heart failure hope

Amgen's chronic heart failure (CHF) drug ivabradine has been granted priority review by the FDA to go along with fast-track status awarded in April, raising hopes of early entry into the US market.The much-anticipated drug works as an inhibitor of the ... [Published PMLive - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

McIntosh rallies to beat Fayette Co. 28-25 in opener

Owen Peacock and the McIntosh defense swarm to the ball. (Staff Photo by Christopher Dunn)The return of the county's oldest rivalry did not disappoint. After a two year hiatus, the McIntosh-Fayette County showdown was renewed with the Chiefs ... [Published Fayette Daily News - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Elliott Levy joins Amgen from BMS

Dr Elliott Levy has left his role at Bristol-Myers Squibb to join Amgen as senior VO, global development.Levy was most recently senior VP and head of specialty development at BMS, where he spent 17 years.During this time he served in a number of senior ... [Published PMLive - Aug 26 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Amgen has appointed new global development head

:07 in Pharmaceutical Company Restructures Amgen has announced the appointment of Elliot Levy as its new senior vice-president for global development, effective as of September 8th 2014. Mr Levy joins the company from Bristol-Myers Squibb, where he worked ... [Published Zenopa - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 2 reports

Data back Amgen drug for overactive thyroid in dialysis patients

A second Phase III trial of Amgen’s AMG 416 has also hit targets showing that the drug is effective in reducing thyroid levels in kidney disease patients receiving dialysis who have developed secondary hyperparathyroidism.Secondary HPT is a common, serious ... [Published Pharma Times - Aug 19 2014]
Entities: Amgen Inc, Dialysis, Thyroid
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

5 Things Amgen, Inc.'s Management Wants You to Know

Amgen ( NASDAQ: AMGN     ) reported its second-quarter earnings results two weeks ago, delivering yet another quarter of impressive growth and boosting full-year guidance.Source: University of Michigan School of Natural Resources & Environment , Fli ... [Published Motley Fool Discussion Boards - Aug 11 2014]
First reported May 22 2014 - Updated May 23 2014 - 1 reports

Blackshades RAT leads to 97 Arrests in 16 countries

On May 19, 2014, the FBI announced a worldwide coordinated action against criminals who created, sold, and used a Remote Administration Trojan (RAT) known as BlackShades. In the FBI's BlackShades Press Release they shared that 40 participating FBI ... [Published Security Bloggers Network - May 22 2014]

More Content

All (29) | News (27) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Amgen Heart Study Shows Positive Ivabradine Res... [Published Drug Discovery and Development - 4 hours ago]
Investigational Ivabradine Treatment Improves C... [Published Pharmacy Times - 6 hours ago]
Amgen applies for EU approval of new melanoma drug [Published Zenopa - Sep 08 2014]
Amgen Submits Cholesterol Drug for EMA Approval [Published Drug Discovery and Development - Sep 03 2014]
Amgen files for EU approval of talimogene laher... [Published Pharma Letter - Sep 03 2014]
Amgen submits next gen cholesterol drug [Published Pharmafocus - Aug 29 2014]
Amgen files for US approval of cholesterol drug... [Published Pharma Letter - Aug 29 2014]
Amgen reports positive data from new cholestero... [Published Zenopa - Aug 29 2014]
Amgen claims first-to-file spot in PCSK9 inhibi... [Published PMLive - Aug 29 2014]
Amgen Seeks Cholesterol Drug Approval [Published Los Angeles Business Journal - Aug 29 2014]
Amgen files cholesterol drug evolocumab in USA [Published Pharma Times - Aug 29 2014]
PCSK9 race heads to the finish line with Amgen'... [Published FierceBiotech - Aug 28 2014]
Amgen Submits BLA For Evolocumab - Quick Facts [Published RTTNews.com - Aug 28 2014]
Amgen gets priority review for chronic heart fa... [Published PMLive - Aug 28 2014]
McIntosh rallies to beat Fayette Co. 28-25 in o... [Published Fayette Daily News - Aug 28 2014]
Amgen Gets FDA Priority Review For Heart Drug -... [Published RTTNews.com - Aug 27 2014]
Amgen heart failure drug gets FDA priority review [Published Pharma Times - Aug 27 2014]
FDA priority review for Amgen’s ivabradine in CHF [Published Pharma Letter - Aug 27 2014]
FDA grants Amgen's ivabradine filing for chroni... [Published FirstWord Pharma - Aug 27 2014]
Elliott Levy joins Amgen from BMS [Published PMLive - Aug 26 2014]
Amgen has appointed new global development head [Published Zenopa - Aug 20 2014]
Further positive Ph III results for Amgen’s AMG... [Published Pharma Letter - Aug 19 2014]
Data back Amgen drug for overactive thyroid in ... [Published Pharma Times - Aug 19 2014]
Amgen Says Second Phase 3 Study Of AMG 416 Meet... [Published RTTNews.com - Aug 18 2014]
5 Things Amgen, Inc.'s Management Wants You to ... [Published Motley Fool Discussion Boards - Aug 11 2014]
U.S. Patents Awarded to Inventors in New York (... [Published Insurance News Net - Aug 11 2014]
Blackshades RAT leads to 97 Arrests in 16 count... [Published Security Bloggers Network - May 22 2014]
Amgen reports positive results of Phase III mel... [Published Pharmaceutical Business Review - Mar 17 2014]
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Published Wall St. Cheat Sheet - Jan 31 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Blackshades RAT leads to 97 Arrests in 16 count... [Published Security Bloggers Network - May 22 2014]
On May 19, 2014, the FBI announced a worldwide coordinated action against criminals who created, sold, and used a Remote Administration Trojan (RAT) known as BlackShades. In the FBI's BlackShades Press Release they shared that 40 participating FBI ...
Amgen’s Cholesterol-Fighting Drug Succeeds Yet ... [Published Wall St. Cheat Sheet - Jan 31 2014]
Amgen Inc.’s ( NASDAQ:AMGN ) experimental anti-cholesterol drug, evolocumab, was successful in its fifth late-stage trial. The treatment targets a protein called PCSK9 that’s typically associated with high levels of “bad” cholesterol (or, LDL),  ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.